These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21700369)

  • 1. New insights into the structural requirements for pro-apoptotic agents based on 2,4-diaminoquinazoline, 2,4-diaminopyrido[2,3-d]pyrimidine and 2,4-diaminopyrimidine derivatives.
    Font M; González Á; Palop JA; Sanmartín C
    Eur J Med Chem; 2011 Sep; 46(9):3887-99. PubMed ID: 21700369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of 2,4,6-functionalized derivatives of pyrido[2,3-d]pyrimidines as cytotoxic agents and apoptosis inducers.
    Sanmartín C; Domínguez MV; Cordeu L; Cubedo E; García-Foncillas J; Font M; Palop JA
    Arch Pharm (Weinheim); 2008 Jan; 341(1):28-41. PubMed ID: 18161903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anhydrous versus hydrated N4-substituted 1H-pyrazolo[3,4-d]pyrimidine-4,6-diamines: hydrogen bonding in two and three dimensions.
    Trilleras J; Quiroga J; Cobo J; Marchal A; Nogueras M; Low JN; Glidewell C
    Acta Crystallogr B; 2008 Oct; 64(Pt 5):610-22. PubMed ID: 18799849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of quinazoline and pyrido[2,3-d]pyrimidine N9-C10 reversed-bridge antifolates in complex with NADP+ and Pneumocystis carinii dihydrofolate reductase.
    Cody V; Galitsky N; Luft JR; Pangborn W; Queener SF; Gangjee A
    Acta Crystallogr D Biol Crystallogr; 2002 Sep; 58(Pt 9):1393-9. PubMed ID: 12198294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.
    Rewcastle GW; Bridges AJ; Fry DW; Rubin JR; Denny WA
    J Med Chem; 1997 Jun; 40(12):1820-6. PubMed ID: 9191958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
    Gangjee A; Vidwans AP; Vasudevan A; Queener SF; Kisliuk RL; Cody V; Li R; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Aug; 41(18):3426-34. PubMed ID: 9719595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of analgesic, anti-inflammatory and ulcerogenic activities of some triazolo- and 2-pyrazolyl-pyrido[2,3-d]-pyrimidines.
    Hafez HN; Abbas HA; El-Gazzar AR
    Acta Pharm; 2008 Dec; 58(4):359-78. PubMed ID: 19103572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N(4)-Methyl-N(4)-(2-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine-ethanol-hydrazine (1/0.865/0.135): hydrogen-bonded ribbons containing four independent ring types.
    Trilleras J; Quiroga J; Cobo J; Glidewell C
    Acta Crystallogr C; 2009 Jun; 65(Pt 6):o293-5. PubMed ID: 19498241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulfur and selenium derivatives of quinazoline and pyrido[2,3-d]pyrimidine: synthesis and study of their potential cytotoxic activity in vitro.
    Moreno E; Plano D; Lamberto I; Font M; Encío I; Palop JA; Sanmartín C
    Eur J Med Chem; 2012 Jan; 47(1):283-98. PubMed ID: 22104973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrido[1,2-a]pyrimidin-4-one derivatives as a novel class of selective aldose reductase inhibitors exhibiting antioxidant activity.
    La Motta C; Sartini S; Mugnaini L; Simorini F; Taliani S; Salerno S; Marini AM; Da Settimo F; Lavecchia A; Novellino E; Cantore M; Failli P; Ciuffi M
    J Med Chem; 2007 Oct; 50(20):4917-27. PubMed ID: 17845019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (E)-3-{2-amino-4-ethoxy-6-[N-(4-methoxyphenyl)-N-methylamino]pyrimidin-5-yl}-1-phenylprop-2-en-1-one: a boat-shaped pyrimidine ring and a chain of hydrogen-bonded R4(2)(8) and R2(2)(20) rings.
    Trilleras J; Quiroga J; Low JN; Cobo J; Glidewell C
    Acta Crystallogr C; 2007 Dec; 63(Pt 12):o758-60. PubMed ID: 18057633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chiral pyrrolo[2,3-d]pyrimidine and pyrimido[4,5-b]indole derivatives: structure-activity relationships of potent, highly stereoselective A1-adenosine receptor antagonists.
    Müller CE; Geis U; Grahner B; Lanzner W; Eger K
    J Med Chem; 1996 Jun; 39(13):2482-91. PubMed ID: 8691445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
    Gangjee A; Adair OO; Queener SF
    J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of pyrrolo[2,3-d]pyrimidin-4-ones as corticotropin-releasing factor 1 receptor antagonists with a carbonyl-based hydrogen bonding acceptor.
    Aso K; Kobayashi K; Mochizuki M; Kanzaki N; Sako Y; Yano T
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2365-71. PubMed ID: 21414781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of tri- or tetrasubstituted pyrimidine derivatives through the [5+1] annulation of enamidines with either N,N-dimethylformamide dialkyl acetals or orthoesters and their application in a ring transformation of pyrimidines to pyrido[2,3-d]pyrimidin-5-one derivatives.
    Sasada T; Aoki Y; Ikeda R; Sakai N; Konakahara T
    Chemistry; 2011 Aug; 17(34):9385-94. PubMed ID: 21780196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological profile of new apoptotic agents based on 2,4-pyrido[2,3-d]pyrimidine derivatives.
    Cordeu L; Cubedo E; Bandrés E; Rebollo A; Sáenz X; Chozas H; Victoria Domínguez M; Echeverría M; Mendivil B; Sanmartin C; Palop JA; Font M; García-Foncillas J
    Bioorg Med Chem; 2007 Feb; 15(4):1659-69. PubMed ID: 17204425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors.
    Liu KK; Huang X; Bagrodia S; Chen JH; Greasley S; Cheng H; Sun S; Knighton D; Rodgers C; Rafidi K; Zou A; Xiao J; Yan S
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1270-4. PubMed ID: 21269826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of N-methyl-4-(4-methoxyanilino)quinazolines as potent apoptosis inducers. Structure-activity relationship of the quinazoline ring.
    Sirisoma N; Pervin A; Zhang H; Jiang S; Adam Willardsen J; Anderson MB; Mather G; Pleiman CM; Kasibhatla S; Tseng B; Drewe J; Cai SX
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2330-4. PubMed ID: 20188546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and anti-tumor activities of some new pyridines and pyrazolo[1,5-a]pyrimidines.
    Ahmed OM; Mohamed MA; Ahmed RR; Ahmed SA
    Eur J Med Chem; 2009 Sep; 44(9):3519-23. PubMed ID: 19398146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New potential inhibitors of cyclin-dependent kinase 4: design and synthesis of pyrido[2,3-d]pyrimidine derivatives under microwave irradiation.
    Tu S; Zhang J; Zhu X; Xu J; Zhang Y; Wang Q; Jia R; Jiang B; Zhang J
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3578-81. PubMed ID: 16621547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.